Lipids, statins, and clinical outcomes in heart failure: rethinking the data

Muthiah Vaduganathan, Stephen J. Greene*, Andrew P. Ambrosy, Mihai Gheorghiade

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Lower serum lipid levels are paradoxically predictive of poor clinical outcomes in hospitalized and ambulatory patients with heart failure (HF). In large randomized controlled trials, statins did not demonstrate an overall mortality benefit in chronic HF patients. We currently lack adequate prospective data that aggressive lipid management in HF truly alters disease course and progression. Despite their traditional use as lipid-lowering agents, hypothesis-generating works have suggested that statins may show benefit in specific enriched HF subgroups. Given that patients hospitalized for HF continue to face a high post-discharge event rate and that statins are increasingly inexpensive, widely available, and generally well tolerated, it is imperative that we identify those HF patients most likely to benefit and reconsider testing these agents in specific subpopulations.

Original languageEnglish (US)
Pages (from-to)695-698
Number of pages4
JournalHeart Failure Reviews
Issue number6
StatePublished - Oct 11 2014


  • Heart failure
  • Lipids
  • Outcomes
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Lipids, statins, and clinical outcomes in heart failure: rethinking the data'. Together they form a unique fingerprint.

Cite this